almost feels like proof of concept validation ?? I thought we were getting hard numbers that may drive a partner deal. What I read was the testing was good enough to do more testing.. SORRY NOT BASHING I am AMBS LONG just thought the news was going to be in a different format validation of the so called gold standard of testing as Gerald Put it not our test was positive so we can do more testing.. Before a possible 1 year from not try at possible commercialization.. ??? Maybe its just me but I am disappointed.. And well Obviously the market is seeing this the same up basically 1/2 cent on what was to be AMBS best news to date......
I see it differently. It tells me that BD has demonstrated they can measure and control the assay as required, that it is reproducable and predictable. They have completed an R&R phase for clinical trials with high level of copnfidence . For medical diagnositc instruments that must be done before a commit can be made to invest in any REAL product development/testing/validations and NPI, etc. This development will vary from one medical device company to another but must follow a protocol. This release tells me that BD and AMBS have come through that. Now they will do a product development and roll out plan. That is probably already underway. If I read this right, momentum will build and, importantly, other compnaies now doing research will have to look carefully at their own plans. Labs, clinics and others will have to be eventually trained, brought up to speed and that takes time and money. Meanwhile other indications will possibly surface.
My read is this is huge. Potentially, this allows clinicians to diagnose and apply information they were previously not able to do and measure the result. Bio investors , stand by.
said Gerald E. Commissiong, President & CEO of Amarantus. "Now that we are establishing an assay with suitable analytical performance characteristics, we have begun the process of looking towards the clinical performance data we believe will ultimately determine the commercial success of LymPro. We believe LymPro has the potential to become a critical component in the diagnosis paradigm of Alzheimer's disease worldwide."